OM
BTAI icon

Opaleye Management’s BioXcel Therapeutics BTAI Stock Holding History

Opaleye Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,875
Closed -$4.98M – 59
2020
Q2 		$4.98M Buy
+5,875
New +$3.83M 1.01% 33

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Opaleye Management's BTAI Position: Q3 2020 in Review

Opaleye Management sold out of BioXcel Therapeutics (BTAI) in Q3 2020, closing a stake of 5,875 shares — an estimated $4.98M sold.

Opaleye Management first reported a position in BTAI in Q2 2020 and held it in 1 quarter. The position peaked at $4.98M in Q2 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q3 2020.

  • Opaleye Management reported no remaining BioXcel Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Opaleye Management sold 5,875 BioXcel Therapeutics shares in Q3 2020, an estimated $4.98M.
  • Opaleye Management first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 1 quarter.
  • Opaleye Management's BioXcel Therapeutics position peaked at $4.98M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2020.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.